Incyte Corporation INCY
123.36
(1.46)
(1.17%)
as of 29 Sep
- Market cap
- $26.1B
- P/E
- 15.4×
Follow INCY
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
Incyte Corporation (INCY) Return on assets
Incyte Corporation's return on assets over the twelve months to 30 June 2026 was 23.6%, up 2.8 percentage points from fiscal 2025 (20.8%). Over the past ten years it has ranged from −15.9% (fiscal 2017) to 22.3% (fiscal 2021); the current reading is higher than 91% of that period. That is above the Biotechnology industry median of −49.2% and above the Healthcare sector median of −30.9%.
Return on assets, annual
Annual
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | 20.8% | 20.22 |
| FY2024 | 0.53% | (8.94) |
| FY2023 | 9.47% | 3.15 |
| FY2022 | 6.32% | (16.01) |
| FY2021 | 22.3% | 30.79 |
| FY2020 | −8.46% | (23.18) |
| FY2019 | 14.7% | 10.29 |
| FY2018 | 4.43% | 20.32 |
| FY2017 | −15.9% | (23.77) |
| FY2016 | 7.88% | 7.16 |
Against its own ten years
Low −15.9%
High 22.3%
Ten-year median
6.32%
Current reading's percentile
91
Return on assets against peers
| Company | Return on assets |
|---|---|
| INCY Incyte Corporation | 23.6% |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 15.3% |
| JAZZ Jazz Pharmaceuticals PLC compare | 8.54% |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | 8.47% |
| GMAB Genmab A/S Sponsored ADR compare | 8.30% |
| RPRX Royalty Pharma PLC compare | 4.26% |
| ROIV Roivant Sciences Ltd. compare | −5.15% |
| BNTX BioNTech SE Sponsored ADR compare | −8.24% |
| INSM Insmed, Inc. compare | −38.2% |
| Biotechnology industry median | −49.2% |
| Healthcare sector median | −30.9% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on INCY
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement